Synergy Pharmaceuticals (NASDAQ:SGYP) released its earnings results on Thursday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01), MarketWatch Earnings reports. The firm had revenue of $11.11 million for the quarter, compared to analyst estimates of $15.65 million.
SGYP traded down $0.09 on Friday, reaching $0.36. 9,599,730 shares of the company’s stock were exchanged, compared to its average volume of 7,622,059. The firm has a market capitalization of $114.13 million, a PE ratio of -0.35 and a beta of 2.38. Synergy Pharmaceuticals has a twelve month low of $0.35 and a twelve month high of $3.10.
A number of analysts have recently commented on the stock. BTIG Research cut shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday, August 7th. Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. Zacks Investment Research lowered shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 10th. Finally, BidaskClub lowered shares of Synergy Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $8.17.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Recommended Story: Relative Strength Index
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.